Valens Semiconductor (VLN) Wheel Strategy Research

Where Valens trades, and why the balance sheet is the story

As of July 23, 2026, Valens Semiconductor (VLN) trades near $1.72, a roughly $187 million company that has ranged between $1.10 and $3.71 over the past year. It sits 54% below its high.

The number that matters most: Valens holds about $86 million in cash and short-term deposits against roughly $8 million of debt. That is $78 million of net cash, about $0.72 per share, or 42% of the entire share price. Take the cash out and the market is paying roughly $109 million for a business that generated $70.7 million of revenue at a 62.2% gross margin.

The buyback most screeners miss

Cash fell from $131 million at the end of 2024 to $92.6 million a year later, which looks alarming until you break it down. Roughly $14.4 million went to operations and $24 million went to buying back its own stock under programmes of $10 million (November 2024) and $15 million (February 2025).

So the company is not burning $38 million a year. It burns about $14 million and chose to return $24 million, roughly 13% of its current market capitalisation, to shareholders. On the operating burn alone the cash funds about six more years, comfortably past the 2027 automotive ramp. Buying back stock while it trades below the value of the cash on hand is accretive to everyone who stays.

Where a cash-secured put would sit

Using the published wheel convention of roughly 0.25 to 0.30 delta and 21 to 45 days, the strikes worth studying sit near $1.50, which is about 13% below the current price and just under the $1.62 twenty-day support shelf. One contract holds $150 of collateral.

There is a live constraint. Valens reports Q2 results on 12 August at 8:30am ET, which falls inside the 21 August expiry. A November expiry clears the event entirely and still carries real open interest. Confirm the date on the company's own investor-relations page before you sell anything, and never sell an option across an earnings report by accident.

The bull and bear case, honestly

Bull case: 42% of the price is cash. Revenue recovered 22% in 2025 after falling 31% in 2024, and Q1 2026 beat on revenue, margin and losses with full-year guidance reaffirmed at $75 to $77 million. Its VA7000 was the first chipset to comply with the open MIPI A-PHY automotive standard the industry is migrating toward. Two of the most accurate semiconductor analysts tracked anywhere, Needham's Quinn Bolton and Oppenheimer's Rick Schafer, both value it at $4.00.

Bear case: it has never been profitable, with $245.5 million of accumulated losses. Growth of roughly 7% a year badly lags a semiconductor industry running near 22%, and over five years revenue has actually declined. Insiders have sold nineteen times and bought zero. Institutional ownership fell 3.88 points last quarter. Automotive revenue is anchored on a single customer, and the A-PHY payoff does not arrive until 2027, which is potentially six more quarters of losses first.

The numbers, four years of them

Revenue collapsed 31% in 2024 and recovered 22% in 2025. That shape is the whole investment case: a cyclical trough followed by a recovery that is under way and not finished.

Look at the R&D column against gross profit. In 2025 the company earned $44.1 million of gross profit and spent $42.7 million on research, about 60% of revenue. That single line explains virtually the entire loss. You can read that either way, but it is a fundamentally different kind of loss from one driven by overhead or stock compensation. If the 2027 automotive ramp lands, this spending is the reason.

Q1 2026, and what August has to prove

The first quarter beat on every line: revenue of $16.9 million above the top of guidance, a GAAP gross margin of 62.2% above the guided range, and an adjusted EBITDA loss of $5.5 million that came in smaller than expected. The stock rose 18% on the print.

• Q2 2026 guidance: revenue $17.2M to $17.6M, gross margin 60% to 62%.
• Full-year 2026 guidance reaffirmed at $75M to $77M.

That full-year number requires a genuine second-half step-up, and it is what the 12 August call will be judged on. Q2 guidance of $17.2M to $17.6M against Q1's $16.9M is only a 2% to 4% sequential move, so most of the year's growth is still ahead of it and unproven.

Who owns it, and who has been selling

This is the part of the file that argues against everything above, and it deserves to be stated plainly.

• Insider selling is one-directional. Nineteen insider sells and zero insider buys over the tracked period. The most recent: a VP of Finance sold 1,458 shares on 20 July 2026. Another insider filed a Form 144 for 3,750 shares on 14 July, after an identical sale in April. Individually these are small and routine, shaped like share-settlement sales. Collectively, the complete absence of a single open-market purchase during a 54% decline is a real signal.
• Institutions are reducing. 48 institutional holders own about 39.1 million shares, but institutional ownership fell to 38.02%, down 3.88 percentage points quarter over quarter. The holder list is high quality, including Value Base, IGP Investments, Clal Insurance, Marshall Wace, Ameriprise, ARK Investment Management, Renaissance Technologies and Squarepoint. The aggregate direction is still out, not in.

What the analysts actually say

Two of the most accurate semiconductor analysts tracked anywhere cover Valens, with no financing relationship to it, and both sit at $4.00 against a $1.72 price.

Their targets have been wrong on timing, the stock is down 29% from its 50-day average since. But the thesis they underwrite is a 2027 event, and that clock has not run out. Analyst accuracy statistics are third-party vendor figures whose methodology differs between providers, and past accuracy does not predict future calls.

A note on reading the option chain

One habit worth taking from this report even if you never trade Valens. Before you judge any option by its quoted implied volatility, check when the contract last actually traded. On thin chains a bid/ask pair can sit unchanged for weeks with no transaction behind it, and any volatility figure derived from that quote is meaningless.

On Valens specifically, the near-the-money August strikes printed during the session and carry 1,700 to 3,200 contracts of open interest, so they describe a live market. One November strike had not traded since 29 June. Its quote is a market-maker placeholder. Also worth knowing: implied volatility solved at the bid is around 107%, not the roughly 197% the midpoint implies. The midpoint is aspirational, the bid is what you would realistically receive.

What would change this

• Q2 revenue below $17.2M, or a cut to the $75M-$77M full-year guide. The thesis breaks, the second-half step-up is the entire 2026 case.
• Gross margin below 60%. A pricing-power question, and the cheap-enterprise-value argument depends on 62% margins holding.
• A named A-PHY production win with an OEM other than Mercedes. De-risks the 2027 case and the customer concentration in one announcement.
• Any insider buying on the open market. Would be the first confirming signal in a year.
• Buybacks suspended, or operating burn above $20M a year. Would materially shorten the runway.

The bottom line

For a put seller this balance is more favourable than it is for a share buyer, because you do not need the stock to rise. You need it to stay above your strike, or to land somewhere you are content to own it. With $0.72 a share of net cash underneath, a strike near $1.50 sits at a price where the downside is cushioned by something real rather than by a story. That is not the same as safe. It is still a lossmaking small-cap that can fall a long way, so size it as speculation.